Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Sichuan University · State Key Laboratory of Biotherapy · +1 more institution
Abstract
Immune checkpoint molecules are promising anticancer targets, among which therapeutic antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment in clinical practice and have great potential. However, this treatment is greatly limited by its low response rates in certain cancers, lack of known biomarkers, immune-related toxicity, innate and acquired drug resistance, etc. Overcoming these limitations would significantly expand the anticancer applications of PD-1/PD-L1 blockade and improve the response rate and survival time of cancer patients. In the present review, we first illustrate the biological mechanisms of the PD-1/PD-L1 immune checkpoints and their role in the healthy…
Citation impact
- FWCI
- 43.78
- Percentile
- 100%
- References
- 327
Authors
7- MWMeng‐Ling WuCorresponding
Sichuan University, State Key Laboratory of Biotherapy
- QHQianrui Huang
Sichuan University, State Key Laboratory of Biotherapy
- YXYao Xie
University of Electronic Science and Technology of China
- XWXuyi Wu
Sichuan University, State Key Laboratory of Biotherapy
- HMHongbo Ma
Sichuan University, State Key Laboratory of Biotherapy
Topics & keywords
- Blockade
- Immunotherapy
- PD-L1
- Tumor microenvironment
- Immune checkpoint
- Medicine
- Immune system
- Downregulation and upregulation
- Good health and well-being